| P50 | author | Fred Saad | Q88065306 |
| P2093 | author name string | Matthew R Smith | |
| | Teuvo L J Tammela | |
| | Benjamin Z Leder | |
| | Blair Egerdie | |
| | Carsten Goessl | |
| | Chunlei Ke | |
| | Paul R Sieber | |
| P2860 | cites work | Metabolic complications of androgen deprivation therapy for prostate cancer | Q24616159 |
| | Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People | Q24633789 |
| | Frailty in older adults: evidence for a phenotype | Q28205094 |
| | Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy | Q33349016 |
| | Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study | Q33677118 |
| | Testosterone, body composition and aging | Q33708584 |
| | Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial | Q34545977 |
| | Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 |
| | Sarcopenic obesity: a new category of obesity in the elderly | Q34768514 |
| | Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels | Q35213002 |
| | Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer | Q36300841 |
| | Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens | Q36684590 |
| | The developmental origins of sarcopenia | Q37119484 |
| | Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives | Q37211844 |
| | Changes in body composition during androgen deprivation therapy for prostate cancer | Q42166232 |
| | Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer | Q42478472 |
| | Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study | Q43726554 |
| | Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer | Q43749401 |
| | Frailty in older men: prevalence, progression, and relationship with mortality | Q43769183 |
| | Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy | Q43980991 |
| | Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer | Q44836371 |
| | Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer | Q46209266 |
| | Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia | Q47446451 |
| | Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer | Q48772932 |
| | Effects of testosterone replacement in hypogonadal men. | Q52970270 |
| | Fatigue in patients with prostate cancer receiving hormone therapy. | Q53519554 |
| | Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. | Q53522491 |
| | Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer | Q53932137 |
| | Testosterone therapy in glucocorticoid-treated men | Q71098016 |
| | Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study--Dual-Energy X-ray Absorptiometry and Body Composition Working Group | Q73074710 |
| | Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men | Q73351479 |
| | Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma | Q74614286 |
| | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy | Q77442914 |
| | Dual-energy X-ray absorptiometry is a valid tool for assessing skeletal muscle mass in older women | Q79923872 |
| | Risk of fracture after androgen deprivation for prostate cancer | Q81264327 |
| | Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer | Q81272515 |
| | Toward a definition of sarcopenia | Q84717467 |
| | Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial | Q84965106 |
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| | sarcopenia | Q1787939 |
| P304 | page(s) | 3271-3276 | |
| P577 | publication date | 2012-05-29 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Sarcopenia during androgen-deprivation therapy for prostate cancer | |
| P478 | volume | 30 | |